Trial: 202103150

3C1 Study: Childhood Cancer Combination Immunotherapy. Phase 1b and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers

Phase

I

Principal Investigator

Abdelbaki, Mohamed

Disease Site

Bones and Joints; Brain and Nervous System; Kidney; Melanoma, Skin; Non-Hodgkin Lymphoma; Soft Tissue

Learn more about this study at: clinicaltrials.gov